Kevin R. Fox, MD, Medical Director, Rena Rowan Breast Center, University of Pennsylvania, Abramson Cancer Center, discusses the role of genomic testing for women with early-stage breast cancer with positive lymph node status, a concept that is already widely accepted for women that are node-negative.

Women that are estrogen receptor-positive with negative lymph nodes make up the largest minority of patients with early-stage breast cancer. Although the genomic tests are not perfect the results can be used to help determine which chemotherapy treatment should be used.

The success of testing in node-negative cancer has raised the question of whether it should be used in node-positive as well. Despite the limited amount of information the premise is that testing is successful regardless of lymph node status.

View more videos of Kevin R. Fox, MD.